Policy & Compliance

  • April 02, 2026

    Georgia Midwifery Laws Violate State Constitution, Suit Says

    A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution. 

  • April 02, 2026

    Chamber Urges 1st Circ. To Affirm Toss Of Tobacco Fee Suit

    A Rhode Island federal judge got it right when she tossed a proposed class action alleging that workers who completed a smoking cessation program are entitled to refunds of surcharges to their health insurance premiums, the U.S. Chamber of Commerce told the First Circuit.

  • April 02, 2026

    Teva $35M Delayed Generic Inhalers Deal Gets Initial OK

    A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.

  • April 01, 2026

    Novo Nordisk Unit Says Ex-Exec's Poor Work Dooms Bias Suit

    By the time she was fired, a finance director of Novo Nordisk unit NNE Inc. had been falling short of company expectations while the pharmaceutical giant was preparing to get a multibillion-dollar drug facility off the ground, NNE's counsel told a North Carolina federal court Wednesday.

  • April 01, 2026

    11th Circ. Backs Order To Fix Fla. System For Disabled Kids

    The Eleventh Circuit upheld an injunction finding Florida's institutionalization of children with complex medical conditions violated the Americans with Disabilities Act, ruling in a split opinion that a lower court mostly didn't abuse its discretion with ordering reforms. 

  • April 01, 2026

    DOL, HHS Must Face Unions' Claims In DOGE Data Suit

    The U.S. Departments of Labor and Health and Human Services must continue facing claims that they illegally gave Elon Musk's Department of Government Efficiency access to employee records, as a D.C. federal judge denied the agencies' bid to escape the union-brought allegations before the trial phase.

  • April 01, 2026

    Harvard Researcher Can Get Docs On Prosecution Motives

    A Massachusetts federal judge ruled Wednesday that a Harvard Medical School researcher and Russian national charged with smuggling frog embryo specimens can see emails and other documents regarding the government's decision to prosecute her, citing evidence the case was "vindictive."

  • April 01, 2026

    NJ Hospital Workers Win Collective Cert. In OT, Break Suit

    A New Jersey healthcare network must face overtime claims on a collective basis, a federal judge ruled, saying a former employee adequately backed up allegations that the network had companywide policies under which it automatically deducted time for meal breaks that weren't taken and left bonuses out of overtime calculations.

  • April 01, 2026

    Sentara Health Strikes $1.5M Deal In Stable Value Fund Suit

    Virginia-based healthcare system Sentara Health will pay $1.5 million to settle a class action claiming it failed to remove an underperforming investment fund from its employee retirement plan, according to federal court filings.

  • April 01, 2026

    PBM Opioid Crisis Suit Stays In Federal Court, Judge Says

    A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.

  • March 31, 2026

    Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law

    A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.

  • March 31, 2026

    Novartis Seeks To Block New Wash. 340B Drug-Pricing Law

    Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.   

  • March 31, 2026

    Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can

    The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.

  • March 31, 2026

    Compound GLP-1s, Anesthesia Prices And More In Court

    Law360 Healthcare Authority looks at appellate arguments from compounding pharmacies alleging they were wrongly barred from making their own versions of weight loss drugs, the Federal Trade Commission's suit over an alleged “rollup” of Texas anesthesiology practices, and other significant litigation developments this week.

  • March 31, 2026

    Medical Center Ousted Worker Over Leg Injury, EEOC Says

    A New Mexico medical center illegally fired an employee after failing to find her a new role that would have better accommodated her leg injury that caused lasting damage, according to a suit the U.S. Equal Employment Opportunity Commission filed Tuesday.

  • March 31, 2026

    Big Insurers Must Face 'Repricing' Antitrust Claims

    Major insurance companies including Aetna, Cigna, Humana and UnitedHealth must face claims they conspired to reduce reimbursements to healthcare providers, a Massachusetts federal judge ruled Monday, finding that the doctors' allegations could constitute antitrust violations.

  • March 31, 2026

    Mich. Judge OKs Bias Training For Healthcare Workers

    A Michigan judge has upheld a state requirement that healthcare professionals undergo implicit bias training to obtain or renew their licenses, finding the mandate was within the state licensing bureau's power.

  • March 31, 2026

    FTC's Probes Of Trans Care Orgs Raise Jurisdiction Concerns

    The Federal Trade Commission's demands for information from transgender care organizations may be exceeding the agency's authority to investigate medical nonprofits.

  • March 31, 2026

    As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt

    A Ninth Circuit ruling on the intersection of two of the most contentious laws in healthcare may be a combustible mix that triggers a new wave of fraud litigation.

  • March 31, 2026

    Insurer Says Yale Was 'Misleading' In $4.1M Transplant Claim

    A Liberty Mutual unit accused Yale University's health system of making "serious and material misstatements" about a plan member's bone marrow transplant, the insurer said in its answer and counterclaim for a declaratory judgment that it can continue to deny the $4.1 million claim.

  • March 31, 2026

    Justices Reject Colorado's LGBTQ+ 'Conversion' Ban

    The U.S. Supreme Court ruled Tuesday that a Colorado ban on therapy intended to change a minor's sexual orientation or gender identity amounts to viewpoint discrimination against a Christian therapist, a finding that split the court's liberal wing and crossed ideological lines.

  • March 30, 2026

    Don't Set Special IP Rules For 'Skinny Labels,' Justices Told

    Drugmakers, industry groups, hospitals and scholars have urged the U.S. Supreme Court to uphold a decision letting a patent suit proceed over a generic drug using a so-called skinny label, saying the generics company is seeking unwarranted special protections that would upend patent law.

  • March 30, 2026

    FCA Qui Tams Are Unconstitutional, Eli Lilly Tells Justices

    The False Claims Act's whistleblower provisions are unconstitutional, drugmaker Eli Lilly has told the U.S. Supreme Court, asking it to overturn a Seventh Circuit decision upholding a $183 million trial win for a whistleblower who claimed the drug company hid how much it charged for Medicaid-covered drugs. 

  • March 30, 2026

    FTC Says Anesthesia Group Cheered While Raising Prices

    The Federal Trade Commission pushed back against a bid from U.S. Anesthesia Partners to avoid facing trial on claims that it monopolized the market through a rollup strategy, saying the company celebrated its ability to dramatically increase prices.

  • March 27, 2026

    5th Circ. Won't Revive Ex-Health IT Co. Worker's Bias Suit

    The Fifth Circuit upheld a healthcare information technology provider's win over a Black former manager's lawsuit claiming she was fired for complaining that a white male colleague was treated better, saying she couldn't overcome the company's rationale for letting her go.

Expert Analysis

  • How Trump Orders Affect Health Orgs.' Care For Trans Minors

    Author Photo

    Two recent executive orders issued by President Donald Trump regarding gender-affirming care for minors have put healthcare organizations in a precarious situation, and these institutions should prepare for various implications and potential scenarios, say attorneys at ArentFox.

  • Reproductive Health Under Trump So Far, And What's Next

    Author Photo

    Based on priorities stated so far, the Trump administration will likely continue to weaken Biden-era policies that protect reproductive health, with abortion, in vitro fertilization and contraception all being issues to watch closely amid a post-Dobbs shift, say attorneys at McDermott.

  • What's Next For Lab Test Regulation Without FDA Authority

    Author Photo

    A recent Texas federal court decision vacating the U.S. Food and Drug Administration's final rule that would apply FDA regulations to laboratory-developed tests signals potential positive impacts in the diagnostic space, and could inspire more healthcare entities to litigate against the government, say attorneys at Hooper Lundy.

  • 6 Criteria Can Help Assess Executive Branch Actions

    Author Photo

    With new executive policy changes announced seemingly every day, several questions can help courts, policymakers and businesses determine whether such actions are proper, effective and in keeping with our democratic norms, say Marc Levin and Khalil Cumberbatch at the Council on Criminal Justice.

  • Learning From COVID-19 Enforcement Against Nursing Homes

    Author Photo

    Five years after the COVID-19 outbreak caused a high number of deaths in nursing homes, an examination of enforcement actions against nursing homes in New York and elsewhere in the country highlights obstacles that may arise when bringing cases of this type, and ways to overcome them, says Kenneth Levine at Stone & Magnanini.

  • How Plan Sponsors Can Mitigate Risk In PBM Contracts

    Author Photo

    A recent lawsuit in New York federal court alleges that JPMorgan caused exorbitant prescription costs by mishandling the pharmacy benefit manager arrangement, adding to a growing body of Employee Retirement Income Security Act fiduciary breach litigation and affirming that fiduciaries must proactively manage their healthcare plan vendors, say attorneys at Hall Benefits Law.

  • 4th Circ. Health Data Ruling Opens Door To State Law Claims

    Author Photo

    In Real Time Medical v. PointClickCare, the Fourth Circuit recently clarified that state law claims can rest in part on violations of a federal law that prohibits electronic health information blocking, expanding legal risks for health IT companies and potentially creating exposure to a range of competitive implications, say attorneys at BCLP.

  • Unpacking Trump Admin Plans For Value-Based Care

    Author Photo

    Recent developments from the Center for Medicare and Medicaid Innovation suggest the Trump administration intends to put its own stamp on value-based care, emphasizing cost savings assessment in particular, with its recent cancellation of several payment models that had supported primary care, says Miranda Franco at Holland & Knight.

  • What To Expect For Stem Cell Regulation Under Trump Admin

    Author Photo

    The new administration's push for deregulation, plus the post-Chevron legal landscape, and momentum from key political and industry players to facilitate stem cell innovation may create an opportune backdrop for a significant reduction in the U.S. Food and Drug Administration's regulatory framework for stem cells, say attorneys at Sheppard Mullin.

  • How Importers Can Minimize FCA Risks Of Tariff Mitigation

    Author Photo

    False Claims Act risks are inherent in many tariff mitigation strategies, making it important for importers to implement best practices to identify and report potential violations of import regulations before they escalate, says Samuel Finkelstein at LMD Trade Law.

  • 10 Practical Takeaways From FDA's Biopharma AI Guidance

    Author Photo

    Recent guidance from the U.S. Food and Drug Administration provides much-needed insight on the usage of artificial intelligence in producing information to support regulatory decision-making regarding drug safety, with implications ranging from life cycle maintenance to AI tool acquisition, say attorneys at Covington.

  • Lawmakers Shouldn't Overlook Rare Disease Therapies' Value

    Author Photo

    As the ORPHAN Cures Act is pending in Congress, policymakers assessing the value of certain drugs for price regulation should consider data beyond what is collected in clinical trials, say Alice Chen at the University of Southern California, and Molly Frean and Yao Lu at Analysis Group.

  • What Trump's Order Means For The Legal Status Of IVF

    Author Photo

    An executive order signed by President Donald Trump last month signals the administration's potential intention to increase protections for in vitro fertilization services, though more concrete actions would be needed to resolve the current uncertainty around IVF access or bring about a binding legal change, says Jeanne Vance at Weintraub Tobin.